Benzinga | Apr 1, 2021 08:07AM EDT

Guardant Health Receives New York State CLEP Approval For Guardant Reveal Blood Test To Detect And Monitor Residual Disease In Patients With Early-Stage Cancer

Guardant Health, Inc. (NASDAQ:GH) announced that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Guardant Reveal(tm) liquid biopsy test for the detection and monitoring of minimal residual disease (MRD) in patients with early-stage cancer (stage II and III). Guardant Reveal is the first blood-only test able to detect, with 7-day turnaround time, a patient's status for residual disease, without the need for a tissue biopsy.